These findings indicate that AT-I may inhibit the JAK2/STAT3 signaling pathway by directly interacting with JAK2 and exerting its activity against CRC cells by inducing apoptosis and metabolic shifts. The gene discussed is JAK2; the disease is colorectal carcinoma.